1-15 of 15
Virginia Kelly
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma

Free
Clinical Trials & Observations
Steven M. Horwitz, Raphael Koch, Pierluigi Porcu, Yasuhiro Oki, Alison Moskowitz, Megan Perez, Patricia Myskowski, Adam Officer, Jacob D. Jaffe, Sara N. Morrow, Kerstin Allen, Mark Douglas, Howard Stern, Jennifer Sweeney, Patrick Kelly, Virginia Kelly, Jon C. Aster, David Weaver, Francine M. Foss, David M. Weinstock
Journal: Blood
Blood (2018) 131 (8): 888–898.
https://doi.org/10.1182/blood-2017-08-802470
Published: 2018
Includes: Supplemental data
Journal Articles

Results from the Phase 3 DUO TM Trial: A Randomized Comparison of Duvelisib Vs Ofatumumab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Free
Ian W. Flinn, MD PhD, Peter Hillmen, MBChB, PhD, Marco Montillo, MD, Zsolt Nagy, MD PhD, Árpád Illés, MD PhD, Gabriel Etienne, MD PhD, Julio Delgado, MD, Bryone Jean Kuss, PhDBMBS,FRCPA,FRACP, Constantine S. Tam, MBBS, MD FRACP, FRCPA, Zoltán Gasztonyi, MD, Fritz Offner, MD, Scott D Lunin, MD, Francesco Bosch, MD, Matthew S. Davids, MD MMSc, Nicole Lamanna, MD, Ulrich Jaeger, MD, Paolo Ghia, Florence Cymbalista, MD, Craig A. Portell, MD, Alan P Skarbnik, MD, Amanda Cashen, MD, Virginia Kelly, MD, Barry Turnbull, PhD, Stephan Stilgenbauer, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 493.
https://doi.org/10.1182/blood.V130.Suppl_1.493.493
Published: 2017
Journal Articles

Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors

Free
Clinical Trials & Observations
Hagop M. Kantarjian, Jorge E. Cortes, Dong-Wook Kim, H. Jean Khoury, Tim H. Brümmendorf, Kimmo Porkka, Giovanni Martinelli, Simon Durrant, Eric Leip, Virginia Kelly, Kathleen Turnbull, Nadine Besson, Carlo Gambacorti-Passerini
Journal: Blood
Blood (2014) 123 (9): 1309–1318.
https://doi.org/10.1182/blood-2013-07-513937
Published: 2014
Includes: Supplemental data
Journal Articles

Health Related Quality of Life of Bosutinib in Imatinib-Resistant or Imatinib-Intolerant Patients with Advanced Chronic Myeloid Leukemia

Free
Jennifer Whiteley, Arlene Reisman, Virginia Kelly, Jorge E Cortes, MD, David Cella, Ph.D.
Journal: Blood
Blood (2012) 120 (21): 4448.
https://doi.org/10.1182/blood.V120.21.4448.4448
Published: 2012
Journal Articles

Patient Perceived Impact of Diarrhea On Health Related Quality of Life in Imatinib-Resistant or Imatinib-Intolerant Patients with Chronic Myeloid Leukemia Treated with Bosutinib

Free
Jennifer Whiteley, Arlene Reisman, Virginia Kelly, Jorge E Cortes, MD, David Cella, Ph.D.
Journal: Blood
Blood (2012) 120 (21): 4451.
https://doi.org/10.1182/blood.V120.21.4451.4451
Published: 2012
Journal Articles

Pharmacokinetics and Tolerability of Bosutinib in Asian Versus Non-Asian Patients with Philadelphia Chromosome–Positive Leukemia

Free
Poe-Hirr Hsyu, Karin Gogat, Ladan Duvillie, Virginia Kelly, Nadine Besson
Journal: Blood
Blood (2012) 120 (21): 4440.
https://doi.org/10.1182/blood.V120.21.4440.4440
Published: 2012
Journal Articles

Bosutinib As Therapy for Chronic Phase Chronic Myeloid Leukemia Following Failure with Imatinib Plus Dasatinib and/or Nilotinib: 24-Month Minimum Follow-up Update

Free
H. Jean Khoury, MD, Carlo Gambacorti-Passerini, Hagop M. Kantarjian, MD, Dong-Wook Kim, David Marin, Pedro E Dorlhiac-Llacer, Andrey Zaritskey, Juan Navarro, Eduardo O Bullorsky, Sarit Assouline, Eric Leip, Virginia Kelly, Kathleen Turnbull, Nadine Besson, Jorge E Cortes, MD
Journal: Blood
Blood (2012) 120 (21): 3785.
https://doi.org/10.1182/blood.V120.21.3785.3785
Published: 2012
Journal Articles

Baseline Predictors of Response to Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib Plus Dasatinib and/or Nilotinib.

Free
Jorge E. Cortes, MD, H. Jean Khoury, Jeff H Lipton, MD, Carlo Gambacorti-Passerini, Tim H Brümmendorf, Dong-Wook Kim, Eric Leip, Virginia Kelly, Nadine Besson, Kathleen Turnbull, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2012) 120 (21): 2793.
https://doi.org/10.1182/blood.V120.21.2793.2793
Published: 2012
Journal Articles

Assessment of Early Cytogenetic Response As a Predictor of Long-Term Clinical Outcomes in a Phase 1/2 Study of Bosutinib in Chronic Phase CML.

Free
Jorge E Cortes, MD, Tim H Brümmendorf, H. Jean Khoury, Andreas Hochhaus, MD, Jane Apperley, Stephen O'Brien, Eric Leip, Virginia Kelly, Katherine Ruffner, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2012) 120 (21): 2798.
https://doi.org/10.1182/blood.V120.21.2798.2798
Published: 2012
Journal Articles

Bosutinib As Therapy for Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib: 36-Month Minimum Follow-up Update

Free
Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Dong-Wook Kim, Anna G Turkina, Zhi-Xiang Shen, H. Jean Khoury, Tim H Brümmendorf, Philippe Schafhausen, Edo Vellenga, Ricardo Pasquini, Vikram Mathews, Tamas Masszi, Simon Durrant, Kimmo Porkka, MD, PhD, Eric Leip, Virginia Kelly, Nadine Besson, Carlo Gambacorti-Passerini
Journal: Blood
Blood (2012) 120 (21): 3779.
https://doi.org/10.1182/blood.V120.21.3779.3779
Published: 2012
Journal Articles

Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure

Free
Clinical Trials & Observations
H. Jean Khoury, Jorge E. Cortes, Hagop M. Kantarjian, Carlo Gambacorti-Passerini, Michele Baccarani, Dong-Wook Kim, Andrey Zaritskey, Athena Countouriotis, Nadine Besson, Eric Leip, Virginia Kelly, Tim H. Brümmendorf
Journal: Blood
Blood (2012) 119 (15): 3403–3412.
https://doi.org/10.1182/blood-2011-11-390120
Published: 2012
Journal Articles

Bosutinib Safety Profile and Management of Toxicities in Leukemia Patients with Resistance or Intolerance to Imatinib and Other Tyrosine Kinase Inhibitors

Free
Hagop M Kantarjian, Jorge E Cortes, Dong-Wook Kim, H. Jean Khoury, Tim H Brümmendorf, Kimmo Porkka, MD, PhD, Giovanni Martinelli, MD, Simon Durrant, Eric Leip, Nadine Besson, Virginia Kelly, Carlo Gambacorti-Passerini, MD
Journal: Blood
Blood (2011) 118 (21): 2760.
https://doi.org/10.1182/blood.V118.21.2760.2760
Published: 2011
Journal Articles

Activity of Bosutinib by Baseline and Emergent Mutation Status in Philadelphia Chromosome–Positive Leukemia Patients with Resistance or Intolerance to Other Tyrosine Kinase Inhibitors

Free
H. Jean Khoury, Jorge E Cortes, Carlo Gambacorti-Passerini, MD, Dong-Wook Kim, Andrey Zaritskey, Andreas Hochhaus, MD, Eric Leip, Nadine Besson, Virginia Kelly, Tim H Brümmendorf
Journal: Blood
Blood (2011) 118 (21): 110.
https://doi.org/10.1182/blood.V118.21.110.110
Published: 2011
Journal Articles

Bosutinib as Third-Line Treatment for Chronic Phase Chronic Myeloid Leukemia Following Failure of Second-Line Therapy with Dasatinib or Nilotinib

Free
H. Jean Khoury, Dong-Wook Kim, MD, Andrey Zaritskey, Carlo Gambacorti-Passerini, Andreas Hochhaus, Juan Navarro, Aaron P. Rapoport, Pedro Enrique Dorlhiac-Llacer, Maria Zanichelli, Virginia Kelly, Nadine Besson, Trevor McMullan, Hagop M. Kantarjian, Jorge E. Cortes
Journal: Blood
Blood (2010) 116 (21): 892.
https://doi.org/10.1182/blood.V116.21.892.892
Published: 2010
Journal Articles

Clinical Activity of Bosutinib by Mutational Status In Patients with Previously Treated Philadelphia Chromosome–positive Leukemias.

Free
Carlo Gambacorti-Passerini, H. Jean Khoury, Helio Pinczowski, Tamas Masszi, MD, PhD, Dong-Wook Kim, MD, Maria Zanichelli, Giovanni Martinelli, Virginia Kelly, Nadine Besson, Trevor McMullan, Tim H. Brummendorf, MD, Jorge E. Cortes
Journal: Blood
Blood (2010) 116 (21): 3434.
https://doi.org/10.1182/blood.V116.21.3434.3434
Published: 2010